Tags

Type your tag names separated by a space and hit enter

Buspirone in the treatment of tardive dyskinesia.
J Clin Psychopharmacol. 1993 Jun; 13(3):204-9.JC

Abstract

Eight patients with mild to severe tardive dyskinesia (TD) were treated for 12 weeks with buspirone in dosages of up to 180 mg/day in an open-label study. Changes in TD severity were assessed by the Abnormal Involuntary Movement Scale. The rater was blind to buspirone dosage. Buspirone was well tolerated by most subjects. A within-subjects comparison of pretreatment and post-treatment Abnormal Involuntary Movement Scale scores revealed a mean improvement of 4.4 (p < 0.01). Improvement was also observed in neuroleptic-induced extrapyramidal side effects such as parkinsonism and akathisia. Scores on the Hamilton Rating Scale for Anxiety and the Brief Psychiatric Rating Scale did not change during the 12-week study. The results of this open-label pilot study suggest that relatively high doses of buspirone may be efficacious in the treatment of TD.

Authors+Show Affiliations

Washington University School of Medicine, Department of Psychiatry, St. Louis, MO 63110.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8102622

Citation

Moss, L E., et al. "Buspirone in the Treatment of Tardive Dyskinesia." Journal of Clinical Psychopharmacology, vol. 13, no. 3, 1993, pp. 204-9.
Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1993;13(3):204-9.
Moss, L. E., Neppe, V. M., & Drevets, W. C. (1993). Buspirone in the treatment of tardive dyskinesia. Journal of Clinical Psychopharmacology, 13(3), 204-9.
Moss LE, Neppe VM, Drevets WC. Buspirone in the Treatment of Tardive Dyskinesia. J Clin Psychopharmacol. 1993;13(3):204-9. PubMed PMID: 8102622.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Buspirone in the treatment of tardive dyskinesia. AU - Moss,L E, AU - Neppe,V M, AU - Drevets,W C, PY - 1993/6/1/pubmed PY - 1993/6/1/medline PY - 1993/6/1/entrez SP - 204 EP - 9 JF - Journal of clinical psychopharmacology JO - J Clin Psychopharmacol VL - 13 IS - 3 N2 - Eight patients with mild to severe tardive dyskinesia (TD) were treated for 12 weeks with buspirone in dosages of up to 180 mg/day in an open-label study. Changes in TD severity were assessed by the Abnormal Involuntary Movement Scale. The rater was blind to buspirone dosage. Buspirone was well tolerated by most subjects. A within-subjects comparison of pretreatment and post-treatment Abnormal Involuntary Movement Scale scores revealed a mean improvement of 4.4 (p < 0.01). Improvement was also observed in neuroleptic-induced extrapyramidal side effects such as parkinsonism and akathisia. Scores on the Hamilton Rating Scale for Anxiety and the Brief Psychiatric Rating Scale did not change during the 12-week study. The results of this open-label pilot study suggest that relatively high doses of buspirone may be efficacious in the treatment of TD. SN - 0271-0749 UR - https://www.unboundmedicine.com/medline/citation/8102622/Buspirone_in_the_treatment_of_tardive_dyskinesia_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=linkout&amp;SEARCH=8102622.ui DB - PRIME DP - Unbound Medicine ER -